Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies

Citation
G. Sechi et al., Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies, PROG NEUR-P, 24(6), 2000, pp. 1043-1051
Citations number
25
Categorie Soggetti
Neurosciences & Behavoir
Journal title
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
ISSN journal
02785846 → ACNP
Volume
24
Issue
6
Year of publication
2000
Pages
1043 - 1051
Database
ISI
SICI code
0278-5846(200008)24:6<1043:RNMSAP>2.0.ZU;2-0
Abstract
1. Conflicting reports are available regarding the sensitivity of patients with Dementia with Lewy bodies (DLB) to risperidone. 2. The authors studied a rare familial case of probable DLB, who developed a documented episode of neuroleptic malignant syndrome (NMS) following the exposure to risperidone. Previously, the patient had had an episode of NMS on trifluoperazine. 3. The discontinuance of risperidone, in combination with a mild increase o f dopaminergic therapy, led to a complete recovery in few days. 4. In patients with DLB, a continued vigilance for extrapyramidal side effe cts, including NMS, would be advisable during the use of risperidone.